2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pain, Postoperative
1
Neoplasms
1
Nalbuphine Allergy
1
Mouth Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia, Biphenotypic, Acute
1
Emergence Delirium
1
Chronic Pain
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
57
Cytarabine
44
fludarabine phosphate
37
Methotrexate
36
Whole-Body Irradiation
32
Mycophenolic Acid
29
Filgrastim
27
fludarabine
25
Vincristine
22
Peripheral Blood Stem Cell Transplantation
22
Cyclosporine
20
Dexamethasone
19
Busulfan
19
Specimen Handling
18
Methylprednisolone
17
venetoclax
16
Granulocyte Colony-Stimulating Factor
16
Tacrolimus
15
Hydrocortisone
15
Daunorubicin
15
Asparaginase
15
merphos
14
Mercaptopurine
14
Melphalan
14
Leucovorin
14
Thiotepa
13
Cord Blood Stem Cell Transplantation
13
Antilymphocyte Serum
13
Calcium Dobesilate
12
Biopsy
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Biphenotypic, Acute
×
Nalbuphine
×
Clear all
NCT03825887
2021-08-02
PCA
Children's Cancer Hospital Egypt 57357
Phase 3
Completed
80 enrolled